<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput xmlns:ns2="local"><serviceExecutionTime>377</serviceExecutionTime><Drug id="57874"><DrugName>avacincaptad pegol sodium</DrugName><DrugNamesKey><Name id="43053733">Zimura</Name><Name id="43063345">avacincaptad pegol</Name><Name id="43053730">avacincaptad pegol sodium</Name></DrugNamesKey><DrugSynonyms><Name><Value>ARC-1905</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>aptamer C5 inhibitors (age-related macular degeneration), Archemix/Ophthotech</Value></Name><Name><Value>avacincaptad pegol sodium</Value><Types><Type>USAN</Type><Type>PINN</Type></Types></Name><Name><Value>Zimura</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>avacincaptad pegol</Value><Types><Type>INN</Type></Types></Name><Name><Value>aptamer C5 inhibitors (age-related macular degeneration), Archemix/IVERIC Bio</Value></Name></DrugSynonyms><CompanyOriginator id="29137">Archemix Corp</CompanyOriginator><CompaniesPrimary><Company id="1033865">IVERIC Bio Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="29137">Archemix Corp</Company></CompaniesSecondary><CrossReferences><SourceEntity id="57874" type="Drug"><TargetEntity id="461001" type="siDrug">Avacincaptad pegol</TargetEntity></SourceEntity><SourceEntity id="1033865" type="Company"><TargetEntity id="4297721792" type="organizationId">Iveric Bio Inc</TargetEntity></SourceEntity><SourceEntity id="29137" type="Company"><TargetEntity id="4298004487" type="organizationId">Archemix Corp</TargetEntity></SourceEntity><SourceEntity id="1226" type="ciIndication"><TargetEntity id="4830" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3067" type="ciIndication"><TargetEntity id="10062766" type="MEDDRA"></TargetEntity><TargetEntity id="827" type="ORPHANET"></TargetEntity><TargetEntity id="-2004310482" type="omicsDisease"></TargetEntity><TargetEntity id="2509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3354" type="ciIndication"><TargetEntity id="D057135" type="MeSH"></TargetEntity></SourceEntity><SourceEntity id="3355" type="ciIndication"><TargetEntity id="4831" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="341" type="ciIndication"><TargetEntity id="10046851" type="MEDDRA"></TargetEntity><TargetEntity id="D014605" type="MeSH"></TargetEntity><TargetEntity id="98715" type="ORPHANET"></TargetEntity><TargetEntity id="-1203341451" type="omicsDisease"></TargetEntity><TargetEntity id="798" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="3518" type="ciIndication"><TargetEntity id="10063381" type="MEDDRA"></TargetEntity><TargetEntity id="2200" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity></SourceEntity><SourceEntity id="127" type="Action"><TargetEntity id="3408" type="Mechanism">Anti-Complement 5 (C5)</TargetEntity></SourceEntity><SourceEntity id="PTGT-00407" type="ciTarget"><TargetEntity id="4001612457283" type="siTarget">C5a anaphylatoxin chemotactic receptor 1</TargetEntity><TargetEntity id="9126" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><IndicationsPrimary><Indication id="3067">Stargardt disease</Indication><Indication id="3355">Dry age related macular degeneration</Indication><Indication id="341">Uveitis</Indication><Indication id="3518">Polypoidal choroidal vasculopathy</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1226">Age related macular degeneration</Indication><Indication id="3354">Wet age related macular degeneration</Indication></IndicationsSecondary><ActionsPrimary><Action id="973">Complement cascade inhibitor</Action><Action id="127">Complement C5a receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="348">PEGylated formulation</Technology><Technology id="620">Ophthalmic formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-06-29T11:45:41.000Z</LastModificationDate><ChangeDateLast>2019-04-17T00:00:00.000Z</ChangeDateLast><AddedDate>2007-08-14T11:12:18.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1033865" linkType="Company"&gt;IVERIC Bio&lt;/ulink&gt; (formerly Ophthotech Corp), under license from &lt;ulink linkID="29137" linkType="Company"&gt;Archemix&lt;/ulink&gt;, is developing avacincaptad pegol sodium (ARC-1905, Zimura), a PEGylated anti-C5 aptamer, for the potential treatment of wet and dry age-related macular degeneration (AMD), polypoidal choroidal vasculopathy, non-infectious uveitis and Stargardt Disease [&lt;ulink linkID="821860" linkType="Reference"&gt;821860&lt;/ulink&gt;], [&lt;ulink linkID="1515441" linkType="Reference"&gt;1515441&lt;/ulink&gt;],  [&lt;ulink linkID="1645929" linkType="Reference"&gt;1645929&lt;/ulink&gt;], [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;], [&lt;ulink linkID="2142299" linkType="Reference"&gt;2142299&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2016, a phase II/III trial was initiated in patients with geographic atrophy secondary to dry AMD [&lt;ulink linkID="1962159" linkType="Reference"&gt;1962159&lt;/ulink&gt;]; in September 2017, the trial was modified to accelerate the  timeline to obtain topline data by reducing the number of patients [&lt;ulink linkID="1963592" linkType="Reference"&gt;1963592&lt;/ulink&gt;]. In March 2015, a phase IIa trial  was initiated in the US, in patients with polypoidal choroidal vasculopathy [&lt;ulink linkID="1645929" linkType="Reference"&gt;1645929&lt;/ulink&gt;]. In January 2018, a phase IIb trial in patients with autosomal recessive Stargardt disease was initiated [&lt;ulink linkID="1997749" linkType="Reference"&gt;1997749&lt;/ulink&gt;]. In July 2017, a phase IIa trial was planned in patients with intermediate/posterior non-infectious uveitis in 2018 [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Ophthotech is also investigating &lt;ulink linkID="61677" linkType="Drug"&gt;ARC-186&lt;/ulink&gt;, an unPEGylated anti-C5 aptamer.&lt;/para&gt;&lt;para&gt;The company was previously developing avacincaptad pegol sodium, a PEGylated anti-C5 aptamer, for the potential treatment of wet  age-related macular degeneration (AMD).    By January 2016, a phase I/IIa trial had  been initiated in patients with wet AMD in combination with anti-VEGF therapy  [&lt;ulink linkID="1736035" linkType="Reference"&gt;1736035&lt;/ulink&gt;]; in July 2017, the company discontinued enrollment in the phase I/IIa trial and was to focus on the initiation of a new phase IIa trial [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;]; in September 2017, the phase IIa trial of avacincaptad pegol sodium in combination with &lt;ulink linkID="22395" linkType="Drug"&gt;ranibizumab&lt;/ulink&gt; in patients with wet-AMD was initiated [&lt;ulink linkID="1963592" linkType="Reference"&gt;1963592&lt;/ulink&gt;]; in May 2018, patient recruitment was complete and topline data were expected  by the end of 2018 [&lt;ulink linkID="2029644" linkType="Reference"&gt;2029644&lt;/ulink&gt;]; in November 2018, data from the phase IIa trial were reported. However, development of the drug for wet AMD was presumed to be  discontinued as the results were intriguing, based on the totality of the data; at that time, the company  announced to focus  the resources on the efficient execution of  other ongoing Zimura clinical programs in geographic atrophy secondary to dry AMD and autosomal recessive Stargardt disease,  &lt;ulink linkID="85152" linkType="Drug"&gt;gene therapy programs in rhodopsin mediated autosomal dominant retinitis pigmentosa and Best disease&lt;/ulink&gt;,  minigene programs in LCA 10 and autosomal recessive Stargardt disease and  the recently acquired &lt;ulink linkID="88553" linkType="Drug"&gt;HtrA1 inhibitor program in dry AMD&lt;/ulink&gt; [&lt;ulink linkID="2093556" linkType="Reference"&gt;2093556&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;Avacincaptad pegol sodium is protected by composition of matter patents  issued in the US, EU, Japan and certain other jurisdictions, which expires in 2025 except in Japan with expiry in 2026. The pending composition of matter patent applications for avacincaptad pegol sodium, if granted, are expected to expire in 2025. Patents covering the treatment of certain complement mediated disorders with avacincaptad pegol sodium, for use in a method of treating certain complement mediated disorders or a composition comprising avacincaptad pegol sodium for treating certain complement mediated disorders, issued in the US, EU, Japan and certain other jurisdictions, expires in 2025 except in Japan with expiry in 2026 [&lt;ulink linkID="1904534" linkType="Reference"&gt;1904534&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Dry AMD&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In  January 2016, a randomized, double-masked, parallel-group, phase II/III trial (&lt;ulink linkID="253814" linkType="Protocol"&gt;NCT02686658&lt;/ulink&gt;; OPH2003) evaluating the safety and efficacy of avacincaptad pegol sodium in subjects (expected n = 300) with geographic atrophy secondary to dry AMD was initiated in the US and Hungary. The primary endpoint was the mean change in best corrected visual acuity. At that time, the first patient was dosed and initial data were expected in December 2018 [&lt;ulink linkID="1962159" linkType="Reference"&gt;1962159&lt;/ulink&gt;], [&lt;ulink linkID="1730140" linkType="Reference"&gt;1730140&lt;/ulink&gt;]. In September 2017, Ophthotech decided to modify the trial. Orignally the trial planned to enroll 300 patients in the initial stage, with an interim analysis scheduled at the 18-month time point, and then enroll up to an additional 600 patients thereafter. The trial would  be modified to accelerate the  timeline to obtain topline data by reducing the number of patients, and  incorporate patients already enrolled in the study [&lt;ulink linkID="1963592" linkType="Reference"&gt;1963592&lt;/ulink&gt;]. By November 2017,  modified clinical trial protocol was submitted to the US FDA. In November 2017, the company planned to enroll only 200 patients, with time point for attaining the primary efficacy endpoint shortened to 12 months. At that time, initial topline data were expected in 2H19 [&lt;ulink linkID="1979865" linkType="Reference"&gt;1979865&lt;/ulink&gt;]. In February 2018, scientific details of the trial   were presented at the 41st Annual Macula Society Meeting in Beverly Hills, CA [&lt;ulink linkID="2032214" linkType="Reference"&gt;2032214&lt;/ulink&gt;]. In August 2018, the trial was ongoing in the US and Hungary [&lt;ulink linkID="1962159" linkType="Reference"&gt;1962159&lt;/ulink&gt;]. By October 2018, 286 patients had been enrolled and patient recruitment was completed in the phase IIb portion of the trial. At that time, initial top-line data were expected in the fourth quarter of 2019 [&lt;ulink linkID="2079533" linkType="Reference"&gt;2079533&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In July 2009, a randomized, open-label phase I study (&lt;ulink linkID="59300" linkType="Protocol"&gt;NCT00950638&lt;/ulink&gt;; OPH2001) was initiated in the US in patients (n = 47) with dry AMD and secondary geographic atrophy in the US. In November 2012, the study was completed [&lt;ulink linkID="1515507" linkType="Reference"&gt;1515507&lt;/ulink&gt;]. In January 2014, clinical data were presented at the 32nd Annual JPMorgan Healthcare Conference in San Francisco, CA. At that time a phase IIa study had been completed. Patients (n = 47) with dry-AMD received avacincaptad pegol sodium (0.3 or 1 mg/eye iv) for five injections. No treatment-related adverse events were reported. The higher dose administered showed a slight trend toward lower geographic atrophy growth than the lower dose group [&lt;ulink linkID="1515441" linkType="Reference"&gt;1515441&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Wet AMD&lt;/subtitle&gt;In September 2017, an open-label, parallel assignment, phase IIa  trial (&lt;ulink linkID="321666" linkType="Protocol"&gt;NCT03362190&lt;/ulink&gt;; OPH2007) to evaluate avacincaptad pegol sodium in combination with &lt;ulink linkID="22395" linkType="Drug"&gt;ranibizumab&lt;/ulink&gt; in patients (n = 64) with neovascular age related wet-macular degeneration (NVAMD) who have not been previously treated with anti-VEGF therapy was initiated in the US, Hungary and Latvia. The primary outcome measure was the assessment of adverse events in a time frame of 6 months.   At that time, the trial was expected to complete in December 2018  [&lt;ulink linkID="1963592" linkType="Reference"&gt;1963592&lt;/ulink&gt;], [&lt;ulink linkID="2029832" linkType="Reference"&gt;2029832&lt;/ulink&gt;]. In November 2017,  initial topline data were expected by the end of 2018 [&lt;ulink linkID="1979865" linkType="Reference"&gt;1979865&lt;/ulink&gt;]. In May 2018, patient recruitment was complete [&lt;ulink linkID="2029644" linkType="Reference"&gt;2029644&lt;/ulink&gt;]. In November 2018, data were reported. Based on a preliminary analysis of the safety data from this trial, Zimura combination therapy was generally well tolerated after six months of treatment. Data demonstrated that in group 1, patients (n = 10) were administered monthly combination therapy consisting of Lucentis 0.5mg followed by Zimura 4mg two days later. In this group, the mean change in visual acuity from baseline at month 6 was 9.0 ETDRS letters with a median of 7.0 letters. 40% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. In group 2, 10 patients were administered monthly combination therapy consisting of Lucentis 0.5mg and Zimura 2mg on the same day, which was the same dosing regimen as the best-performing group from the previously completed phase 1/2a trial. In this group, the mean change in visual acuity from baseline at month 6 was 10.2 ETDRS letters with a median of 16.0 letters. 60% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. In group 3, during the induction phase (Day 1 – Month 2), 22 patients were administered Lucentis 0.5mg followed by Zimura 2mg on the same day followed by Zimura 2mg, 14 days later. During a subsequent maintenance phase (Month 3 – Month 5), patients were administered Lucentis 0.5mg followed by Zimura 2mg on the same day. In this group, the mean change in visual acuity from baseline at month 6 was 10.7 ETDRS letters with a median of 10.0 letters. 40.9% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain. In group 4, during the induction phase (Day 1 – Month 2) 22 patients were administered Lucentis 0.5mg followed by Zimura 2mg on the same day followed by Zimura 2mg fourteen days later. During a subsequent maintenance phase (Month 3 – Month 5) patients were administered Zimura 2mg followed two days later by Lucentis 0.5mg and Zimura 2mg. In this group, the mean change in visual acuity from baseline at month 6 was 9.9 ETDRS letters with a median of 11.0 letters. 18.2% of patients gained greater than or equal to three lines of vision, or 15 ETDRS letters, defined as significant visual gain; However, development of the drug for wet AMD was presumed to be discontinued as the results were intriguing, based on the totality of the data; at that time, the company  announced to focus  the resources on the efficient execution of  other ongoing Zimura clinical programs in geographic atrophy secondary to dry AMD and autosomal recessive Stargardt disease,  gene therapy programs in rhodopsin mediated autosomal dominant retinitis pigmentosa and Best disease,  minigene programs in LCA 10 and autosomal recessive Stargardt disease and  the recently acquired HtrA1 inhibitor program in dry AMD [&lt;ulink linkID="2093556" linkType="Reference"&gt;2093556&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2016, data from a phase I/IIa trial in wet AMD patients were reported demonstrated 60% of the patients had significant vision gain with avacincaptad pegol sodium 2mg dose at week 24 [&lt;ulink linkID="1736035" linkType="Reference"&gt;1736035&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By January 2014, a phase II study was planned for avacincaptad pegol sodium in combination with Fovista in patients with wet AMD [&lt;ulink linkID="1515441" linkType="Reference"&gt;1515441&lt;/ulink&gt;]. In February 2014, a phase II trial for avacincaptad pegol sodium and Fovista in combination with anti-VEGF therapy for the treatment of anti-VEGF resistant wet AMD patients was scheduled to initiate in 2015 [&lt;ulink linkID="1529642" linkType="Reference"&gt;1529642&lt;/ulink&gt;]. In January 2016, the 18-month, treatment burden reduction trial was initiated  in patients (expected n = 45) with wet AMD [&lt;ulink linkID="1736035" linkType="Reference"&gt;1736035&lt;/ulink&gt;]. In July 2017, the company discontinued enrollment in the phase IIa trial and focus on the initiation of new phase IIa trial [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2008, a non-randomized, open-label, 2-year, uncontrolled, phase I trial (&lt;ulink linkID="19447" linkType="Protocol"&gt;NCT00709527&lt;/ulink&gt;; OPH2000) was planned in the US which would assess safety, tolerability and pharmacokinetics. Subjects (n = 60) with subfoveal choroidal neovascularization secondary to AMD would receive multiple doses of avacincaptad pegol sodium by intravitreal injection, in combination with one or multiple doses of &lt;ulink linkID="22395" linkType="Drug"&gt;ranibizumab&lt;/ulink&gt;  (0.5 mg/eye). The primary outcome would be  dose-limiting toxicity, with the  safety endpoints including adverse events, vital signs, and ophthalmic variables. The trial was estimated to complete in December 2010 [&lt;ulink linkID="923168" linkType="Reference"&gt;923168&lt;/ulink&gt;]. In October 2008, the company began enrollment in the trial [&lt;ulink linkID="956450" linkType="Reference"&gt;956450&lt;/ulink&gt;]. In March 2009, further information was presented at IBC's Fifth International Ocular Angiogenesis and Retinal Degeneration Conference in Las Vegas, NV. Subjects were to receive three monthly doses of avacincaptad pegol sodium (0.03, 0.3, 1.5 and 3.0 mg/eye) along with a monthly injection of ranibizumab. Inclusion criteria included visual acuity of between 20/63 and 20/200 and a lesion size of 5 disc areas (DA) or less. Five subjects had been treated by this time and no drug-related serious adverse events had been observed [&lt;ulink linkID="999981" linkType="Reference"&gt;999981&lt;/ulink&gt;]. In May 2009, clinical data were presented at the 2009 ARVO Annual Meeting in Fort Lauderdale, FL. In 17 patients who had received one dose of avacincaptad pegol sodium in combination with ranibizumab  the mean visual acuity increased from 49 letters at baseline to +9.5 letters at 4-weeks post-treatment, and the mean optical tomography center point thickness increased from 324 microM at baseline to -104 microM at week 4 post-treatment. No acute toxicity or drug-related adverse events were reported [&lt;ulink linkID="1002255" linkType="Reference"&gt;1002255&lt;/ulink&gt;]. In March 2011, the trial was completed [&lt;ulink linkID="923168" linkType="Reference"&gt;923168&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Stargardt Disease&lt;/subtitle&gt;In July 2017, a randomized, controlled trial in patients with Stargardt Disease was expected to commence before the end of 2017 [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;]. In November 2017, a randomized, double-masked, sham-controlled, phase IIb trial was expected to begin before the end of 2017 [&lt;ulink linkID="1979865" linkType="Reference"&gt;1979865&lt;/ulink&gt;]. In January 2018, the first patient was enrolled in the US phase IIb trial (&lt;ulink linkID="321943" linkType="Protocol"&gt;NCT03364153&lt;/ulink&gt;; OPH2005) in patients (expected n = 120) with autosomal recessive Stargardt disease. The primary endpoint was the mean rate of change in the area of ellipsoid zone defect as measured by en face spectral domain optical coherence tomography (SD-OCT) at 18 months. At that time, the trial was expected to complete in September 2020 and top-line data were expected in 2020 [&lt;ulink linkID="1997811" linkType="Reference"&gt;1997811&lt;/ulink&gt;], [&lt;ulink linkID="1997749" linkType="Reference"&gt;1997749&lt;/ulink&gt;]. In March 2018, scientific details of the trial were presented at the International Symposium on Ocular Pharmacology and Therapeutics in Tel-Aviv, Israel and in April 2018,  at the 2018 Annual Meeting of the Association for Research in Vision and Ophthalmology in Honolulu, HI [&lt;ulink linkID="2032214" linkType="Reference"&gt;2032214&lt;/ulink&gt;]. In February 2019, enrollment of patients was completed and top-line data were expected in the second half of 2020 [&lt;ulink linkID="2123518" linkType="Reference"&gt;2123518&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Idiopathic polypoidal choroidal vasculopathy&lt;/subtitle&gt;In July 2017, the company expected to initiate a phase IIa trial in patients with idiopathic polypoidal choroidal vasculopathy to assess Zimura in combination with anti-VEGF therapy by the end of 2017 [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;]. In November 2017, approximately 20 patients were to be enrolled in the combination study of Zimura and Eylea (&lt;ulink linkID="53547" linkType="Drug"&gt;aflibercept&lt;/ulink&gt;). At that time, initial topline data were expected in the second half of 2019 [&lt;ulink linkID="1979865" linkType="Reference"&gt;1979865&lt;/ulink&gt;]. In December 2017, the randomized, open-label,  parallel group, phase IIa trial (&lt;ulink linkID="322928" linkType="Protocol"&gt;NCT03374670&lt;/ulink&gt;; OPH2006) was initiated in the US, in elderly patients (expected n = 20), to assess the safety of  Zimura  in combination with Eylea. At that time, the trial was expected to complete in December 2019 [&lt;ulink linkID="1997371" linkType="Reference"&gt;1997371&lt;/ulink&gt;]. In August 2018, the trial was ongoing [&lt;ulink linkID="1997371" linkType="Reference"&gt;1997371&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In March 2015, an open label,  single group assignment, phase IIa trial (&lt;ulink linkID="225314" linkType="Protocol"&gt;NCT02397954&lt;/ulink&gt;; OPH2002) was initiated in the US, in patients (n = 4) with idiopathic polypoidal choroidal vasculopathy, to assess the safety and efficacy of avacincaptad pegol sodium in combination with anti-VEGF therapy. In October 2015, the trial was completed [&lt;ulink linkID="1645929" linkType="Reference"&gt;1645929&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Uveitis&lt;/subtitle&gt;In July 2017, Ophthotech planned to initiate a phase IIa trial in patients with intermediate/posterior non-infectious uveitis in 2018 [&lt;ulink linkID="1948477" linkType="Reference"&gt;1948477&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In June 2007, preclinical data were presented at the AAPS National Biotech meeting in San Diego, CA. A dual-capture, hybridization-based pseudo-ELISA assay was developed to detect and quantify the PEGylated anti-C5 aptamer, avacincaptad pegol sodium [&lt;ulink linkID="821860" linkType="Reference"&gt;821860&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3355">Dry age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-01-31T00:00:00.000Z</StatusDate><Source id="1962159" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3355">Dry age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-01-31T00:00:00.000Z</StatusDate><Source id="1962159" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3518">Polypoidal choroidal vasculopathy</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2015-03-24T00:00:00.000Z</StatusDate><Source id="1645929" type="TRIALREG"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3067">Stargardt disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-01-16T00:00:00.000Z</StatusDate><Source id="1997749" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="341">Uveitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-07-26T00:00:00.000Z</StatusDate><Source id="1948477" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-11-12T00:00:00.000Z</StatusDate><Source id="2093556" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-11-12T00:00:00.000Z</StatusDate><Source id="2093556" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1033865">IVERIC Bio Inc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2018-11-12T00:00:00.000Z</StatusDate><Source id="2093556" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29137">Archemix Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3355">Dry age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-13T00:00:00.000Z</StatusDate><Source id="821691" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="29137">Archemix Corp</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-13T00:00:00.000Z</StatusDate><Source id="821691" type="PR"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3355">Dry age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2009-07-30T00:00:00.000Z</StatusDate><Source id="1515507" type="TRIALREG"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3355">Dry age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-13T00:00:00.000Z</StatusDate><Source id="821691" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-08-13T00:00:00.000Z</StatusDate><Source id="821691" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3067">Stargardt disease</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-07-26T00:00:00.000Z</StatusDate><Source id="1948477" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="1226">Age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2008-10-27T00:00:00.000Z</StatusDate><Source id="956450" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2016-01-14T00:00:00.000Z</StatusDate><Source id="1736035" type="OTHER"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-09-19T00:00:00.000Z</StatusDate><Source id="1963592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1033865">IVERIC Bio Inc</Company><Country id="LV">Latvia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3354">Wet age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2017-09-19T00:00:00.000Z</StatusDate><Source id="1963592" type="PR"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="29137">Archemix Corp</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1226">Age related macular degeneration</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">2007-06-26T00:00:00.000Z</StatusDate><Source id="821860" type="OTHER"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00407"><Name>Complement C5a receptor</Name><SwissprotNumbers><Swissprot>O70129</Swissprot><Swissprot>P21730</Swissprot><Swissprot>P30992</Swissprot><Swissprot>P30993</Swissprot><Swissprot>P79175</Swissprot><Swissprot>P79188</Swissprot><Swissprot>P79234</Swissprot><Swissprot>P79240</Swissprot><Swissprot>P97520</Swissprot><Swissprot>Q9TUE1</Swissprot></SwissprotNumbers></Target><Target id="PTGT-34137"><Name>Complement cascade</Name><SwissprotNumbers></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1033865">IVERIC Bio Inc</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="13794">Ajinomoto Co Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="29137">Archemix Corp</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="6">Drug - Manufacturing/Supply</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><Deals><Deal id="110046" title="Ophthotech to develop Archemix's aptamer C5 inhibitors for ophthalmic disease worldwide         "></Deal><Deal id="235456" title="Ajinomoto Althea to provide clinical and commercial fill/finish services to Ophthotech's Fovista and Zimura               "></Deal></Deals><PatentFamilies><PatentFamily id="1067871" number="WO-2005079363" title="Aptamer therapeutics useful in the treatment of complement-related disorders"></PatentFamily><PatentFamily id="2474671" number="WO-2006088888" title="Aptamer therapeutics useful in the treatment of complement-related disorders"></PatentFamily><PatentFamily id="3939749" number="US-20180030446" title="Aptamer therapeutics useful in the treatment of complement-related disorders"></PatentFamily><PatentFamily id="4135968" number="US-20180207233" title="Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics"></PatentFamily><PatentFamily id="4405159" number="WO-2019040397" title="Method for treating or preventing neovascular age-related macular degeneration"></PatentFamily><PatentFamily id="4515981" number="WO-2019099786" title="A method for treating or preventing idiopathic polypoidal choroidal vasculopathy (IPCV)"></PatentFamily><PatentFamily id="59077" number="WO-2007103549" title="Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>2</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="IVERIC Bio Inc" id="1033865"></CompanyLink><CountAsOwner>5</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>5</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Archemix LLC" id="1159980"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Macregen Inc" id="1168683"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Archemix Corp" id="29137"></CompanyLink><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordsOutput>